Format

Send to

Choose Destination
Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:58-62. doi: 10.1016/j.ejogrb.2014.05.021. Epub 2014 Jun 2.

Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset.

Author information

1
Departments of Obstetrics and Gynecology, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: j.akkermans@me.com.
2
Departments of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; The Child and Family Research Institute, University of British Columbia, Vancouver, Canada.
3
Department of Epidemiology, University of Groningen, University Medical Center, Groningen, The Netherlands.
4
Departments of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, The Netherlands.
5
Departments of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada; The Child and Family Research Institute, University of British Columbia, Vancouver, Canada.
6
The Robinson Institute, School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, Australia.
7
Departments of Obstetrics and Gynecology, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.

Abstract

OBJECTIVE:

The internally validated fullPIERS model predicts adverse maternal outcomes in women with pre-eclampsia within 48h after eligibility. Our objective was to assess generalizability of this prediction model.

STUDY DESIGN:

External validation study using prospectively collected data from two tertiary care obstetric centers.

METHODS:

The existing PETRA dataset, a cohort of women (n=216) with severe early-onset pre-eclampsia, eclampsia, HELLP syndrome or hypertension-associated fetal growth restriction was used. The fullPIERS model equation was applied to all women in the dataset using values collected within 48h after inclusion. The performance (ROC area and R-squared) of the model, risk stratification and calibration were assessed from 48h up to a week after inclusion.

RESULTS:

Of 216 women in the PETRA trial, 73 (34%) experienced an adverse maternal outcome(s) at any time after inclusion. Adverse maternal outcome was observed in 32 (15%) cases within 48h and 62 (29%) within 7 days after inclusion. The fullPIERS model predicted adverse maternal outcomes within 48h (AUC ROC 0.97, 95% CI: 0.87-0.99) and up to 7 days after inclusion (AUC ROC 0.80, 95% CI: 0.70-0.87).

CONCLUSIONS:

The fullPIERS model performed well when applied to the PETRA dataset. These results confirm the usability of the fullPIERS prediction model as a 'rule-in' test for women admitted with severe pre-eclampsia, eclampsia, HELLP syndrome or hypertension-associated fetal growth restriction. Future research should focus on intervention studies that assess the clinical impact of strategies using the fullPIERS model.

KEYWORDS:

Patient care management; Pre-eclampsia; Prognosis; Validation

PMID:
24965981
DOI:
10.1016/j.ejogrb.2014.05.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center